Chronic myelomonocytic leukaemia

5 trials 1 recruiting MedDRA PT
5 Registered trials
1 Recruiting
4 Unique sponsors
9 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 2
M Musculoskeletal (ATC M) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Monoclonal antibody (immune) 1 substance
Antimetabolite 1 substance
BCL-2 inhibitor 1 substance
Phase III: 1 Phase II: 2 Phase I (First in Human): 2

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Taiho Oncology Inc. Commercial
    AZACITIDINE; AZACITIDINE, CEDAZURIDINE
    2024-515098-93-00 7 countries 2025 n=588
    Recruiting

Phase II

2 trials
  • Novartis Pharma AG Commercial
    SABATOLIMAB
    2024-515281-14-00 6 countries 2023 n=18
    Ended
  • Taiho Oncology Inc. Commercial
    DECITABINE, CEDAZURIDINE
    2024-516293-29-01 8 countries 2022 n=100
    Ended

Phase I (First in Human)

2 trials
  • AstraZeneca AB Commercial
    AZD2962
    2025-520786-44-00 1 country 2025 n=7
    Halted
  • Institut De Recherches Internationales Servier IRIS Commercial
    ALLOPURINOL; RASBURICASE; S227928; VENETOCLAX
    2024-514356-33-00 3 countries 2025 n=54
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Taiho Oncology Inc. Commercial 2 Phase II, Phase III 1
Novartis Pharma AG Commercial 1 Phase II 0
AstraZeneca AB Commercial 1 Phase I (First in Human) 0
Institut De Recherches Internationales Servier IRIS Commercial 1 Phase I (First in Human) 0
New trials by year
2022
1
2023
1
2025
3
← All indication landscapes